Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation reports developments as a global medical technology company focused on neurosurgery and tissue reconstruction. News commonly covers quarterly financial results, revenue guidance, operational execution, supply reliability, quality-management work and product availability across its medical technology portfolio.
Company updates also include clinical evidence and medical-conference activity for wound reconstruction products such as PriMatrix Dermal Scaffold, Integra Dermal Matrices, Cytal Wound Matrix, MicroMatrix and AmnioExcel. Recurring corporate topics include leadership appointments, investor conference presentations, manufacturing progress and segment activity within Codman Specialty Surgical and Tissue Technologies.
Integra LifeSciences (Nasdaq: IART) announced that CFO Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 4:20pm PT. A live webcast will be available on the Integra investor relations site under Events & Presentations.
Integra LifeSciences (NASDAQ: IART) announced a leadership transition effective May 1, 2026: Stuart M. Essig has been appointed president and chief executive officer and will continue as chairman, succeeding Mojdeh Poul, who is pursuing other opportunities. Michael McBreen is named chief commercial officer to lead the global commercial organization.
The Board said this is a permanent leadership step and will not initiate a CEO search. Mr. Essig previously served as Integra CEO (1997–2012) and has chaired the Board since 2012.
Integra LifeSciences (Nasdaq: IART) reported Q1 2026 results: revenue $391.9M (+2.4% reported, +1.3% organic), GAAP EPS $(0.06), and adjusted EPS $0.54. Adjusted EBITDA was $76.2M (19.4% of revenue). Company reaffirmed 2026 revenue guidance of $1.662B–$1.702B and raised adjusted EPS guidance to $2.40–$2.50.
Net debt was $1.6B, liquidity ~$488M, and management transitions included Stuart Essig as CEO and Michael McBreen as Chief Commercial Officer.
Integra LifeSciences (NASDAQ: IART) will release first quarter 2026 financial results on Tuesday, May 5, 2026 prior to market open. Management will host a conference call at 8:30 a.m. ET with a live webcast available on the company's Investors website.
Registration is available for dial-in details and replay will be posted on the Investors section following the call.
Integra LifeSciences (Nasdaq: IART) will present new real-world data on PriMatrix dermal scaffold at three April 2026 conferences.
Highlights include analyses from 985 cases involving 117 surgeons, plus a 23-patient burn case series, covering diabetic foot ulcers, complex wounds and mixed-thickness burns.
Integra LifeSciences (NASDAQ: IART) reported Q4 2025 revenues of $434.9M (down 1.7% reported; -2.5% organic) and GAAP EPS of $(0.02). Full-year 2025 revenues were $1,635.2M (up 1.5% reported; -0.7% organic) and GAAP EPS was $(6.74), driven by a $511M goodwill impairment.
Adjusted EPS were $0.83 in Q4 and $2.23 for 2025. Net debt was $1.6B with 4.5x leverage and year-end liquidity ~$516M. 2026 guidance: revenue $1,662M–$1,702M and adjusted EPS $2.30–$2.40, with expected $25–$30M savings from the transformation plan.
Integra LifeSciences (Nasdaq: IART) announced Feb 17, 2026 executive appointments: Teshtar Elavia named corporate vice president and newly created chief technology officer, Michael Hutchinson appointed executive vice president and chief legal officer, and Kerri DiPietro named corporate vice president and chief quality officer.
The CTO role will align R&D with strategic imperatives, accelerate product development, and strengthen the innovation pipeline; Hutchinson will lead legal, compliance and ESG; DiPietro will oversee global quality and a Compliance Master Plan.
Integra LifeSciences (NASDAQ: IART) will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to market open. Management will host a conference call at 8:30 a.m. ET with a live webcast on the company Investor site.
Investors can register to receive dial-in details and a PIN; joining 10 minutes early is recommended. A webcast replay will be posted on the Investors section following the call.
Integra LifeSciences (Nasdaq: IART) said CEO Mojdeh Poul and CFO Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 2:15 p.m. ET (11:15 a.m. PT).
A live webcast of the presentation will be available on Integra LifeSciences' investor relations website under Events & Presentations.
Integra LifeSciences (Nasdaq: IART) announced that CEO Mojdeh Poul and CFO Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025 at 10:30 a.m. ET. A live webcast will be available on the company investor relations website under Events & Presentations.